Chandan Healthcare Limited (NSE SME)
Feb 10, 2025 - Feb 12, 2025
| Price | ₹151 - ₹159 |
| Premium | ₹0 |
|---|---|
| Lot size | 800 |
| Allotment | Feb 13, 2025 |
| Listing | Feb 17, 2025 |
| Category | Lot(s) | Qty | Amount | Reserved |
|---|---|---|---|---|
| Retail | 1 | 800 | 127200 | 2699 |
| HNI | 2 | 1600 | 254400 | 1157 |
Last updated on 12-Feb-2025 17:00:23
| Category | Offered | Applied | Times |
|---|---|---|---|
| QIB | 1233600 | 9356800 | 7.58 |
| NIB | 925600 | 17791200 | 19.22 |
| RETAIL | 2159200 | 5272800 | 2.44 |
| EMPRET | 245600 | 51200 | 0.21 |
| Total | 4564000 | 32472000 | 7.11 |
| Application Wise Breakup | |
|---|---|
| Category | App. Received |
| QIB | 12 |
| NIB | 457 |
| RETAIL | 6591 |
| EMPRET | 39 |
| Total | 7099 |
| Subscription Demand (in ₹ crore) | |||
|---|---|---|---|
| Category | Offered | Demand | Times |
| QIB | 19.61 | 148.77 | 7.58 |
| NIB | 14.72 | 282.88 | 19.22 |
| RETAIL | 34.33 | 83.84 | 2.44 |
| EMPRET | 3.91 | 0.81 | 0.21 |
| Total | 72.57 | 516.3 | 7.11 |
| QIB Interest Cost Per Share (7 Days) | |||||
|---|---|---|---|---|---|
| @7% ₹1.6 | @8% ₹1.8 | @9% ₹2.1 | @10% ₹2.3 | @11% ₹2.5 | @12% ₹2.8 |
| HNI Interest Cost Per Share (7 Days) | |||||
|---|---|---|---|---|---|
| @7% ₹4.1 | @8% ₹4.7 | @9% ₹5.3 | @10% ₹5.9 | @11% ₹6.4 | @12% ₹7 |
IPO Details
| Total Issue Size | 67,52,000 shares(aggregating up to 107.36 Cr) |
| Fresh Issue | 44,52,064 shares (aggregating up to 70.79 Cr) |
| Offer for Sale | 22,99,936 shares of 10(aggregating up to 36.57 Cr) |
| Issue Type | Book Built Issue IPO |
| Listing At | NSE SME |
| Share Holding Pre Issue | 2,00,00,000 shares |
| Share Holding Post Issue | 2,44,52,064 shares |
| Market Maker Portion | 3,39,200 shares |
| Market Maker | R.K.Stock Holding Private Limited |
IPO Reservation
| Investor Category | Shares Offered |
|---|---|
| QIB Shares Offered | Not more than 50% of the Net Offer |
| Retail Shares Offered | Not less than 35.00% of the Net Offer |
| NII (HNI) Shares Offered | Not less than 15.00% of the Net Offer |
Key Performance Indicators
| KPI | Dec-24 | Mar-24 | Mar-23 |
|---|---|---|---|
| ROE | 33.83% | 47.50% | 13.11% |
| ROCE | 27.17% | 35.20% | 15.61% |
| RONW | 29.74% | 39.54% | 12.31% |
| EPS (basic) | 8.07 | 8.14 | 1.68 |
| P/E Pre IPO | 19.44 | ||
| P/E Post IPO | 16.76 |
Financial Details In Crores
| Period Ended | Dec-24 | Mar-24 | Mar-23 | Mar-22 |
|---|---|---|---|---|
| Assets | 170 | 129 | 98 | 81 |
| Revenue | 168 | 178 | 137 | 120 |
| Profit After Tax | 17 | 16 | 4 | -1 |
| Net Worth | 41 | 27 | 24 | |
| Reserves and Surplus | 34 | 21 | 7 | 4 |
| Total Borrowing | 52 | 42 | 21 | 17 |
About Company
Chandan Healthcare Limited, incorporated in September 2003, operates a network of diagnostic centres across North India, offering comprehensive pathology and radiology testing services. As of December 31, 2024, the company runs one flagship laboratory, seven central laboratories, and twenty-six satellite centres, supported by over three hundred collection centres across 23 cities in Uttar Pradesh and more than 19 in Uttarakhand. The company provides a wide range of 1,496 tests, including 481 routine pathology tests in basic biochemistry and haematology, along with 1,015 specialized tests such as immunohistopathology and molecular pathology. Additionally, it offers 545 radiology tests, covering x-rays, ultrasonography, CT, MRI, and advanced CT scans, supported by eleven CT scanners and four MRI machines. Chandan Healthcare employs a team of 15 radiologists, 23 pathologists, and over 161 other qualified professionals, ensuring high-quality diagnostic services across its extensive network.
Unistone Capital Pvt Ltd
Strong Regional Presence – Extensive network across North India, including 39 tier-two cities and towns in Uttarakhand, ensuring widespread accessibility.
Comprehensive Diagnostics Services – Integrated provider of pathology, radiology testing, and medical consultations, offering a diverse range of 1,496 tests.
Proven Financial Stability – Consistent profitability and strong financial performance, reinforcing long-term business sustainability.
Operational Dependency on Flagship Centres – Any disruption at key diagnostic centres could impact test processing, affecting business operations and financial performance.
Brand Reliance – The company’s growth and prospects depend on maintaining and strengthening its brand image, which could be affected by market competition or service issues.
Customer Concentration & Short-Term Contracts – A significant portion of revenue comes from B2C and a few key customers, with no long-term contracts, posing a risk of revenue fluctuation if agreements are not renewed.
Phone: 04067162222, 04079611000
Email: chl.ipo@kfintech.com
Website: https://kosmic.kfintech.com/ipostatus/